Using EZH2 inhibition to improve chemotherapy effectiveness in ovarian cancer
Official title: Project 1: EZH2 Inhibition to Prevent/Overcome Chemoresistance
Funded at University of Pittsburgh at Pittsburgh · NIH-10925278 · Data updated 2026-11-12
This study is looking at how blocking a protein called EZH2 might help ovarian cancer patients who aren't responding well to chemotherapy, by focusing on certain cells in the tumor environment that make treatment less effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $487,172 |
| NIH project number | 5P50CA272218-02 |
| Project ID | NIH-10925278 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are ovarian cancer patients who have experienced chemotherapy resistance.
✕Less likely to help
Patients with non-ovarian cancers or those who have not undergone chemotherapy may not benefit from this research.
What this research studies
This research investigates how inhibiting a specific protein called EZH2 can help overcome chemotherapy resistance in ovarian cancer patients. The study focuses on the tumor microenvironment, particularly the role of certain stromal cells that contribute to resistance against platinum-based chemotherapy. By targeting these cells and their supportive properties, the research aims to enhance the effectiveness of treatment and improve patient outcomes. Patients may be involved in trials that assess the impact of EZH2 inhibitors on their cancer response.
Why it matters
Potential benefit: If successful, this research could lead to improved chemotherapy responses and better survival rates for ovarian cancer patients.
How similar studies have gone: Other research has shown promising results in targeting tumor microenvironments to overcome chemotherapy resistance, indicating that this approach has potential for success.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Edwards, Robert Page — University of Pittsburgh at Pittsburgh
- Study coordinator: Edwards, Robert Page
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.